Literature DB >> 17916010

Effects of oral administration of furosemide and torsemide in healthy dogs.

Yasutomo Hori1, Fumihiko Takusagawa, Hiromi Ikadai, Masami Uechi, Fumio Hoshi, Sei-ichi Higuchi.   

Abstract

OBJECTIVE: To investigate the diuretic effects, tolerability, and adverse effects of furosemide and torsemide after short- and long-term administration in healthy dogs. ANIMALS: 8 mixed-breed dogs. PROCEDURES: In a crossover study, furosemide (2 mg/kg), torsemide (0.2 mg/kg), or placebo (bifidobacterium [1 mg/kg]) was administered orally to each dog every 12 hours for 14 days. Blood and urine samples were collected before the study (baseline data) and at intervals on the 1st (short-term administration) and 14th day (long-term administration) of treatment for assessment of urine volume and specific gravity and selected clinicopathologic variables including BUN, creatinine, and aldosterone concentrations, and creatinine clearance.
RESULTS: Compared with the baseline value, short-term administration of furosemide or torsemide immediately increased urine volume significantly; after long-term administration of either drug, urine specific gravity decreased significantly. Compared with the effect of placebo, the 24-hour urine volume was significantly increased after short-term administra-tion of furosemide or torsemide. In addition, it was significantly increased after long-term administration of torsemide, compared with that of short-term administration. Long-term administration of furosemide or torsemide increased the BUN and plasma creatinine con-centrations, compared with the baseline value. Compared with the baseline value, plasma aldosterone concentration was significantly increased after long-term administration of either drug and was significantly higher after torsemide treatment than after furosemide treatment. CONCLUSIONS AND CLINICAL RELEVANCE: In dogs, diuretic resistance developed after 14 days of furosemide, but not torsemide, administration; however, both loop diuretics were associated with increased BUN and plasma creatinine concentrations, compared with values before treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916010     DOI: 10.2460/ajvr.68.10.1058

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  14 in total

1.  Safety of torasemide in healthy adult dogs administered daily for 26 weeks.

Authors:  Evelyne Coussanes; Emilie Guillot; Reynald Magnier; Anne Geneteau; Jonathan Elliott
Journal:  J Vet Pharmacol Ther       Date:  2021-11-17       Impact factor: 1.567

2.  Short-Term Efficacy and Safety of Torasemide and Furosemide in 366 Dogs with Degenerative Mitral Valve Disease: The TEST Study.

Authors:  V Chetboul; J-L Pouchelon; J Menard; J Blanc; L Desquilbet; A Petit; S Rougier; L Lucats; F Woehrle
Journal:  J Vet Intern Med       Date:  2017-10-04       Impact factor: 3.333

3.  Long-term Stability of a Compounded Suspension of Torsemide (5 mg/mL) for Oral Administration.

Authors:  D Adin; P R Johnson; C H Kim; T Nguyenba; S Rosen
Journal:  J Vet Intern Med       Date:  2017-09-15       Impact factor: 3.333

4.  ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs.

Authors:  Bruce W Keene; Clarke E Atkins; John D Bonagura; Philip R Fox; Jens Häggström; Virginia Luis Fuentes; Mark A Oyama; John E Rush; Rebecca Stepien; Masami Uechi
Journal:  J Vet Intern Med       Date:  2019-04-11       Impact factor: 3.333

5.  Role of electrolyte concentrations and renin-angiotensin-aldosterone activation in the staging of canine heart disease.

Authors:  Darcy Adin; Kari Kurtz; Clarke Atkins; Mark G Papich; Shelly Vaden
Journal:  J Vet Intern Med       Date:  2019-11-26       Impact factor: 3.333

6.  Plasma renin activity and aldosterone concentration in dogs with acquired portosystemic collaterals.

Authors:  Yumi Sakamoto; Manabu Sakai; Keita Sato; Toshihiro Watari
Journal:  J Vet Intern Med       Date:  2019-11-14       Impact factor: 3.333

7.  The diuretic torasemide does not prevent aldosterone-mediated mineralocorticoid receptor activation in cardiomyocytes.

Authors:  Basile Gravez; Antoine Tarjus; Ruben Jimenez-Canino; Soumaya El Moghrabi; Smail Messaoudi; Diego Alvarez de la Rosa; Frederic Jaisser
Journal:  PLoS One       Date:  2013-09-09       Impact factor: 3.240

Review 8.  Review of Diagnostic and Therapeutic Approach to Canine Myxomatous Mitral Valve Disease.

Authors:  Giulio Menciotti; Michele Borgarelli
Journal:  Vet Sci       Date:  2017-09-26

9.  Pharmacokinetic and pharmacodynamic properties of orally administered torsemide in healthy horses.

Authors:  Gustavo F Agne; Seung Woo Jung; Anne A Wooldridge; Susan H Duran; William Ravis; Ramiro Toribio
Journal:  J Vet Intern Med       Date:  2018-05-17       Impact factor: 3.333

10.  Population Pharmacokinetics and Pharmacodynamics Modeling of Torasemide and Furosemide After Oral Repeated Administration in Healthy Dogs.

Authors:  Ludovic Pelligand; Emilie Guillot; Anne Geneteau; Jerome Guyonnet; Reynald Magnier; Jonathan Elliott; Mathieu Peyrou; Matthieu Jacobs
Journal:  Front Vet Sci       Date:  2020-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.